Sebaceous Tumors of the Skin and Muir Torre Syndrome – A Mini-Review

Ayesha Arshad, MD, Christopher A. D’Angelis, MD, PhD


Sebaceous glands develop along with hair follicles as part of the folliculo-sebaceous unit and are present in all hair-bearing skin.  Sebum, the product of sebaceous glands, participates in the overall barrier function skin and its production appears in large part is regulated by hormonal levels.  Common tumors derived from sebocytes range from hyperplasia to benign neoplasms to invasive malignancies with metastatic potential.  Additionally, sebaceous neoplasms with unique clinical and histologic features are now recognized as part of the phenotype of the autosomal dominant cancer pre-disposition syndrome, Muir-Torre Syndrome.  Here we review the clinico-pathologic features of benign and malignant tumor of sebaceous origin including an overview of the current molecular basis and clinical management of Muir-Torre Syndrome.


sebaceous adenoma, sebaceous carcinoma, sebaceoma, Muir-Torre Syndrome

Full Text:



Bolognia JL, Jorizzo JL, Rapini PR, eds. Dermatology. 2nd ed. New York: Mosby; 2008.

Imperato-McGinley J, Gautier T, Cai LQ, Yee B, Epstein J, Pochi P. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab. 1993;76(2):524-528.

Schachner LA, Hansen RC, eds. Pediatric Dermatology. 3rd ed. New York: Mosby; 2003.

Dasgupta T, Wilson LD, Yu JB. A Retrospective Review of 1349 Cases of Sebaceous Carcinoma. Cancer. 2009;115(1):158-165.

Deprez M, Uffer S. Clinicopathological features of eyelid skin tumors. A retrospective study of 5504 cases and review of literature. Am J Dermatopathol. 2009;31(3):256-262.

Orta L, Klimstra D, Jing Qin, et al. Towards identification of Hereditary DNA mismatch repair deficiency: Sebaceous Neoplasm Warrants Immunohistochemical screening regardless of patients age or other clinical characteristics. Am J Surg Pathol. 2009;33(6):934-944.

Shalin S, Lyle S, Calonie E, Lazar AJ. Sebaceuos neoplasia and the Muir-Torre Syndrome: important connections with clinical implications. Histopathology. 2010;56(1):133-147.

Abbott J, Hernandez-Rios P, Amirkhan R, Hoang MP. Cystic Sebaceous Neoplasms in Muir-Torre Syndrome. Arch Pathol Lab Med. 2003;127(5):614-617.

Ritten A, Burgdorf W, Hugel H, et al. Cystic Sebaceous Tumors as Marker Lesions for the Muir-Torre Syndrome: A Histopathologic and Molecular Genetic Study. Am J Dermatopathol. 1999;21(5):405-413.

Kruse R, Rutten A, Schweiger N, et al. Frequency of Microsatellite Instability In unselected Sebaceous Gland Neoplasia and Hyperplasia. J Invest Dermatol. 2003;120(5):858-864.

Jones B, Oh C, Mangold E, et al. Muir-Torre Syndrome Diagnostic and Screening guidelines. Australas J Dermatol. 2006;47(4):266-269.

Singh S, Grayson W, Redston M, et al. Site and Tumor type predicts DNA Mismatch Repair Status in cutaneous Sebaceous Neoplasia. Am J Surg Pathol. 2008;32(6):936-942.

Abbas O, Mahalingam M. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a Diagnostic algorithm. J Cutan Pathol. 2009;36(6):613-619.

Weber T. Clinical Surveillance recommendations adopted for HNPCC. Lancet. 1990;548-465.

Ponti G, Ponz de Leon M. Muir Torre Syndrome. Lancet Oncol. 2005;6(12):980.

Lynch HT, Lynch PM, Lanspa SJ. Review of the Lynch syndrome: history, Molecular genetics, screening, differential diagnosis and medicolegal ramifications. Clin Genet. 2009;76(1):1-18.

Kruse R, Rutton A, Lambert C, et al. Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary non colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet. 1998;63(1):63-70.

Schwartz RA, Torre DP. The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol. 1995;33(1):90-104.

Cohen PR, Kohn SR, Kuzrock R. Association of sebaceous gland tumors and internal malignancy: the Muir-Torre Syndrome. Am J Med. 1991;90(5):606-613.

Rulon DB, Helwig EB. Multiple Sebaceous neoplasms of the skin: an association with multiple visceral carcinomas, especially of the colon. Am J Clin Pathol. 1973;60(6):745-753.

Heald B, Plesec T, Lui X, et al. Implementation of Universal Microsatellite Instability and Immunohistochemistry Screening for diagnosing Lynch Syndrome in a large Academic Medical Center. J Clin Onc. 31(10):1336-1340.

Baudhuin LM, Burgart LJ, Leontovich O, Thibodeau SN. Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer. 2005;4(3):255-265.

Cesinaro AM, Ubiali A, Singhinolfi P, et al. Mismatch repair proteins expression and microsatellite instability in skin lesions with sebaceous differentiation: a study in different clinical subgroups with and without cutaneous cancer. Am J Dermatopathol. 2007;29(4):351-358.

Entius MM, Keller JJ, Drillenburg P, et al. Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre Syndrome. Clin Cancer Res. 2000;6(5):1784-1789.

Mangold M, Pagenstecher C, Leister M, et al. A genotype-phenotype correlation of HNPCC: strong predominance of MSH2 mutations in 41 patients with Muir-Torre syndrome. J Med Genet. 2004;41(7):567-572.


  • There are currently no refbacks.